Biobanking for Translational Diabetes Research in India

Area of Science:

• Biomedical research
• Translational medicine
• Biobanking

Background:

• India faces a significant diabetes burden, earning the title of the world's diabetic capital.
• High-quality, clinically annotated biospecimens, particularly peripheral blood mononuclear cells (PBMCs), are essential for advancing diabetes research.
• Existing biobanks in India cater to various diseases, but a dedicated diabetes-specific research repository is notably absent.

Purpose of the Study:

• To highlight the critical need for a diabetes-specific biobank in India.
• To outline the requirements for establishing and maintaining a high-quality biobank for diabetes research.
• To emphasize the importance of integrating clinical data and adopting new technologies for effective biobanking.

Main Methods:

• Reviewing the current landscape of biobanking in India concerning diabetes research.
• Identifying essential components for a functional biobank, including quality standards, governance, and ethical considerations.
• Exploring the role of technology and private sector involvement in developing sustainable biobanks.

Main Results:

• The lack of a dedicated diabetes biobank hinders translational research in India.
• Implementing Good Clinical Laboratory Practices (GCLP) and "certification or accreditation programs" is vital for biospecimen quality.
• Addressing ethical concerns, ensuring robust governance, and securing financial resources are key to biobank sustainability.

Conclusions:

• India must establish a diabetes-specific biobank, learning from global models and adapting to local needs.
• Collaboration between public and private sectors, alongside adoption of new technologies, is essential for creating a cost-effective and long-standing biobank.
• Such a biobank will significantly advance diabetes research, diagnostics, and treatment strategies in India.